A 56-year-old man visits his primary care provider due to intense pain and swelling in his… — USMLE Step 3

A $56$ -year-old man visits his primary care provider due to intense pain and swelling in his right great toe that began abruptly overnight. He reports that the pain is so severe he cannot tolerate the weight of a bedsheet on his foot. The patient underwent a deceased-donor kidney transplantation $3$ years ago for end-stage renal disease secondary to hypertensive nephrosclerosis. His maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and prednisone ( $5\text{ mg}$ daily). His other medications include amlodipine and low-dose aspirin. Vital signs show a temperature of $37.3^\circ\text{C}$ ( $99.1^\circ\text{F}$ ), blood pressure of $134/82\text{ mmHg}$ , and heart rate of $88/\text{min}$ . Examination of the right lower extremity reveals marked erythema, edema, and exquisite tenderness localized to the first metatarsophalangeal joint. Recent laboratory testing demonstrates a serum creatinine of $1.6\text{ mg/dL}$ , which is unchanged from his baseline over the past year. Serum uric acid is $9.2\text{ mg/dL}$ . An arthrocentesis of the affected joint yields cloudy fluid with a leukocyte count of $32,000/\text{mm}^3$ ( $85\%$ neutrophils). A Gram stain shows no organisms. Polarized light microscopy demonstrates numerous negatively birefringent, needle-shaped crystals. Which of the following is the most appropriate initial pharmacologic intervention for this patient's joint symptoms?

A
Oral naproxen
B
Intravenous vancomycin and ceftriaxone
Intra-articular triamcinolone acetonideAnswer
D
Oral colchicine
E
Oral allopurinol

Answer

The most appropriate initial pharmacologic intervention is the administration of an intra-articular glucocorticoid, such as triamcinolone acetonide.

The correct answer utilizes a localized therapy to treat the acute inflammatory gout flare while entirely bypassing the high-risk systemic pharmacokinetics of the patient's transplant regimen. Intra-articular glucocorticoids are highly effective for monoarticular gout and pose no risk of drug-drug interactions with tacrolimus, nor do they compromise the transplanted kidney's hemodynamics.

Step-by-Step Solution

Diagnose the patient's acute presentation.

The acute onset of severe monoarticular pain, erythema, and swelling in the first metatarsophalangeal joint (podagra), combined with synovial fluid showing negatively birefringent needle-shaped crystals, confirms an acute gout flare.

Establishing the definitive diagnosis prevents inappropriate interventions, such as treating for presumed septic arthritis based on an elevated synovial leukocyte count alone.

Identify the patient's complex medical background and current pharmacological regimen.

The patient is a renal transplant recipient on maintenance immunosuppression, critically including the calcineurin inhibitor tacrolimus.

Standard acute gout therapies carry severe, potentially life-threatening risks when used in the setting of solid organ transplantation and calcineurin inhibitors.

Evaluate standard gout therapies against the patient's specific contraindications.

NSAIDs are contraindicated due to the risk of exacerbating tacrolimus-induced afferent arteriole vasoconstriction and causing acute allograft rejection/injury. Colchicine is contraindicated because tacrolimus inhibits its clearance via P-gp and CYP3A4, risking fatal toxicity.

Ruling out unsafe systemic options narrows the choices to localized therapies or alternative systemic agents.

Select the safest, most effective intervention.

Intra-articular triamcinolone acetonide.

Since the flare is limited to a single easily accessible joint, a localized glucocorticoid injection provides rapid relief while avoiding systemic drug interactions and nephrotoxicity.

Key Concept

Management of acute gout in solid organ transplant recipients requires avoiding NSAIDs (which worsen calcineurin inhibitor nephrotoxicity) and colchicine (which reaches toxic levels due to calcineurin inhibitor-mediated CYP3A4 and P-gp inhibition); intra-articular glucocorticoids are the preferred safe alternative.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic